treatment of breast cancer without the MDR-1 genetic modification and transplantation 
outlined in this program of therapy and patients can recieve the taxol therapy without 
participating in this program. 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an opportunity to ask any questions concerning the investigational drug 
regimen involved and the investigator has been willing to reply to my inquiries. This 
investigational drug regimen will be administered under the above numbered, titled and 
described clinical research protocol at this institution. I hereby authorize Dr. 
, the attending physician/investigator and designated associates to 
administer this investigational drug regimen. 
8. I have been told and understand that my participation is voluntary. I may decide not to 
participate, or withdraw my consent and discontinue my participation at any time. Such 
action will be without prejudice and there shall be no penalty or loss of benefits to which 
I may otherwise be entitled, and I will continue to receive treatment by my physician at 
this institution. 
Should I decide not to participate or withdraw my consent from participation in this 
clinical research, I have been advised that I should discuss the consequences or effects 
of my decision with my physician. 
In addition, I understand that the investigator may discontinue the clinical research study 
if, in the sole opinion and discretion of the investigator, the study or treatment offers me 
little or no future benefit, or the supply of medication ceases to be available or other 
causes prevent continuation of the clinical research study. The investigator will notify me 
should such circumstances arise and my physician will advise me about available 
treatment which may be of benefit at that time. 
I will be informed of any new findings developed during the course of this clinical 
research study, which may relate to my willingness to continue participation in the study. 
9. I have been assured that confidentiality will be preserved except that qualified monitors 
from the Food and Drug Administration and the National Cancer Institute may review 
my records where appropriate and necessary. Qualified monitors shall include assignees 
authorized by the Surveillance Committee of this institution provided that confidentiality 
is assured and preserved. My name will not be revealed in any reports or publications 
resulting from this study, without my expressed consent. 
10. I have been informed that should I suffer any injury as a result of participation in this 
research activity, reasonable medical facilities are available at this institution. I 
understand, however, that I cannot expect to receive any credit or reimbursement for 
expenses from this institution or any financial compensation from this institution for such 
injury. 
Recombinant DNA Research, Volume 19 
[541] 
